• Cholecystokinin-Octapeptide Restores Morphine-Impaired LTP i

  2026-05-28

  The reference study demonstrates that cholecystokinin-octapeptide (CCK-8) can restore morphine-induced impairment of hippocampal long-term potentiation (LTP) in rats, with CCK2 receptor mediation. This work provides mechanistic insight into how CCK-8 influences synaptic plasticity under opioid challenge, informing future research on memory impairment and the broader neurobehavioral roles of CCK peptides.

• TBK1 Inhibition Reduces Microglial Pyroptosis in Painful Dia

  2026-05-27

  This study reveals that TANK-binding kinase 1 (TBK1) drives microglial pyroptosis and contributes causally to painful diabetic neuropathy (PDN) in murine diabetes models. Targeted TBK1 inhibition—either by siRNA or amlexanox—attenuates PDN symptoms by suppressing neuroinflammation, suggesting new therapeutic avenues for diabetic neuropathy.

• XPO1 Inhibition by Eltanexor Reduces Colorectal Tumorigenesi

  2026-05-27

  The referenced study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, impairs Wnt/β-catenin signaling to markedly reduce colorectal cancer (CRC) tumorigenesis in preclinical models. This work provides mechanistic and in vivo evidence supporting nuclear export inhibition as a chemopreventive approach in CRC, with translational implications for researchers studying nuclear export in cancer.

• QNZ (EVP4593): Pioneering NF-κB Modulation for Translational

  2026-05-26

  This thought-leadership article explores the mechanistic rationale and strategic utility of QNZ (EVP4593)—a potent quinazoline derivative NF-κB inhibitor—for translational researchers. We examine how nuanced NF-κB pathway modulation enables advances in anti-inflammatory and neurodegenerative disease models, critically evaluate the landscape of NF-κB inhibitors, and provide actionable experimental and translational guidance. By integrating recent evidence from infection control research and practical workflow insights, this article delivers a forward-looking perspective that surpasses conventional product resources.

• Vacuolin-1: Redefining Lysosomal Exocytosis Inhibition Strat

  2026-05-26

  Explore how Vacuolin-1, a leading lysosomal exocytosis inhibitor, enables advanced experimental control over membrane fusion and signaling disruptions. This article reveals deeper assay design principles and translational implications beyond what existing resources cover.

• Gepotidacin: Workflow Enhancements for Antibacterial Researc

  2026-05-25

  Gepotidacin (GSK2140944) is redefining antibacterial research with its novel mechanism targeting bacterial DNA replication, making it a powerful tool for studying resistance and next-generation antibiotic development. This guide details experimental workflows, actionable troubleshooting, and protocol optimizations to unlock Gepotidacin’s full potential in high-impact laboratory settings.

• Sulfo-Cy3 NHS Ester: Reliable Fluorescent Labeling for Cell

  2026-05-25

  This article provides a scenario-driven, evidence-based overview of Sulfo-Cy3 NHS ester (SKU A8107) for protein and peptide labeling in cell viability and cytotoxicity assays. Drawing on published data and practical lab workflows, we examine how this hydrophilic fluorescent dye addresses reproducibility, sensitivity, and compatibility challenges for biomedical researchers.

• DiscoveryProbe Bioactive Compound Library Plus: Optimizing H

  2026-05-24

  Leverage the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) to accelerate high-throughput screening and mechanism-driven discovery in cancer, immunology, and beyond. This article breaks down experimental workflows, practical troubleshooting, and the unique value of integrating advanced ligand screening methods for multidimensional pathway analysis.

• NIR-Activated Cobalt Single-Atom Enzymes for Multimodal Canc

  2026-05-23

  This study introduces a near-infrared (NIR)-triggered cobalt single-atom enzyme (Co-SAE) anchored on hollow N-doped carbon spheres for synergistic photodynamic, photocatalytic, and photothermal therapy in head and neck cancer. The work demonstrates how atomically dispersed Co-SAE enables enhanced generation of reactive oxygen species (ROS) and mild hyperthermia, optimizing antitumor efficacy while preserving tissue function.

• DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P

  2026-05-22

  Faced with common challenges in cell viability and pathway screening, biomedical researchers rely on the validated performance of DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P). This article explores real laboratory scenarios and demonstrates how SKU L1022P delivers reproducible, high-throughput results for apoptosis, cancer, and signaling pathway studies.

• Nilotinib (AMN-107): Unlocking Tumor Immunogenicity in Cance

  2026-05-22

  Explore how Nilotinib (AMN-107) advances cancer research beyond kinase inhibition, revealing new mechanisms for enhancing tumor immunogenicity and immunotherapy efficacy. This piece offers expert insight grounded in recent scientific breakthroughs.

• RWJ 67657: Precision Inhibition in p38 MAPK Assays

  2026-05-21

  RWJ 67657 (JNJ-3026582) sets a new standard for p38 MAP kinase pathway research, uniting potent, selective kinase blockade with a novel acceleration of dephosphorylation. Its unique dual-action mechanism empowers reproducible inflammatory disease modeling and advanced cytokine profiling workflows.

• Cinoxacin: Quinolone Antibiotic Workflows for Gram-Negative

  2026-05-21

  Cinoxacin, a benchmark quinolone antibiotic from APExBIO, delivers reproducible, high-fidelity results in Gram-negative urinary tract infection and resistance studies. This guide translates cutting-edge reference findings into stepwise protocols, advanced applications, and troubleshooting strategies for superior experimental outcomes.

• Prochlorperazine-Induced Hemidystonia: Lessons from a Stroke

  2026-05-20

  The reference study documents a rare case of prochlorperazine-induced hemidystonia in a pregnant patient, initially misdiagnosed as acute ischemic stroke. This work underscores the diagnostic challenges posed by stroke mimics and highlights the need for careful medication history and multidisciplinary assessment to avoid inappropriate interventions.

• CKI 7 dihydrochloride: Advanced Casein Kinase 1 Inhibition i

  2026-05-20

  Explore how CKI 7 dihydrochloride, a potent Casein kinase 1 inhibitor, enables sophisticated modulation of Wnt and circadian signaling in oncology research. This article offers a deep analysis of the latest mechanistic findings and practical guidance for experimental design.

579 records 10/39 page Previous Next First page 上5页 678910 下5页 Last page